Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43850   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A 24-week, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy with 104-Week Open-Label Extension

    Summary
    EudraCT number
    		 2011-004419-22
    Trial protocol
    		 DE   CZ   HU   EE   SK   BG  
    Global end of trial date
    31 Jul 2014

    Results information
    Results version number
    		 v1(current)
    This version publication date
    28 Jun 2016
    First version publication date
    07 Aug 2015
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    VX11-509-102
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01590459
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, Massachusetts, United States, 02210-1862
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, 1 617-341-6777, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    18 Sep 2014
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Jul 2014
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To evaluate the efficacy of multiple doses of VX-509 when administered for 12 weeks in subjects with active RA on stable MTX therapy. To evaluate the safety and tolerability of multiple doses of VX-509 when administered for 12 weeks in subjects with active RA on stable MTX therapy.
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    		 Subjects had been receiving MTX coadministered with folic or folinic acid (at least 5 mg/week) for at least 12 weeks before screening, and had been receiving MTX at a stable dose between 10 mg and 25 mg, orally or subcutaneously administered, per week for at least 8 consecutive weeks.
    Evidence for comparator
    		 There was no active comparator.
    Actual start date of recruitment
    01 May 2012
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    		 Safety, Efficacy
    Long term follow-up duration
    		 2 Years
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 15
    Country: Number of subjects enrolled
    Bulgaria: 40
    Country: Number of subjects enrolled
    Czech Republic: 29
    Country: Number of subjects enrolled
    Estonia: 16
    Country: Number of subjects enrolled
    Germany: 14
    Country: Number of subjects enrolled
    Hungary: 24
    Country: Number of subjects enrolled
    Mexico: 41
    Country: Number of subjects enrolled
    Poland: 39
    Country: Number of subjects enrolled
    Romania: 3
    Country: Number of subjects enrolled
    Russian Federation: 21
    Country: Number of subjects enrolled
    Serbia: 14
    Country: Number of subjects enrolled
    Slovakia: 1
    Country: Number of subjects enrolled
    Ukraine: 18
    Country: Number of subjects enrolled
    United States: 83
    Worldwide total number of subjects
    358
    EEA total number of subjects
    166
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    295
    From 65 to 84 years
    63
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 A total of 359 subjects were enrolled, of which 358 subjects received study drug. Subjects with less than a 20% reduction from baseline in tender joints, swollen joints, and subject-assessed pain at Week 8 or later were eligible to enroll in Escape arm and received 150 mg VX-509 qd or 200 mg VX-509 qd.

    Period 1
    Period 1 title
    24 Week Treatment Period
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Placebo
    Arm description
    		 VX-509-matched placebo up to 24 weeks.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509-matched placebo up to 24 weeks.

    Arm title
    		 VX-509 100 mg qd
    Arm description
    		 VX-509 100 milligram (mg) once daily (qd) up to 24 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-509
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509 100 mg qd up to 24 weeks.

    Arm title
    		 VX- 509 150 mg qd
    Arm description
    		 VX-509 150 mg qd up to 24 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-509
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509 150 mg qd up to 24 weeks.

    Arm title
    		 VX-509 200 mg qd
    Arm description
    		 VX-509 200 mg qd up to 24 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-509
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509 200 mg qd up to 24 weeks.

    Arm title
    		 VX-509 100 mg bid
    Arm description
    		 VX-509 100 mg twice daily (bid) for up to 24 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-509
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509 100 mg bid up to 24 weeks.

    Number of subjects in period 1
    		Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Started
    71
    71
    72
    72
    72
    Completed
    58
    57
    60
    59
    61
    Not completed
    13
    14
    12
    13
    11
         Physician decision
    1
    2
    -
    -
    -
         Death
    -
    -
    -
    -
    1
         Did not meet eligibility criteria
    1
    1
    -
    2
    -
         Adverse event
    6
    6
    7
    9
    3
         Noncompliance with study drug
    -
    1
    -
    -
    -
         Unspecified
    1
    1
    -
    -
    -
         Lost to follow-up
    2
    1
    -
    -
    1
         Refused further dosing for reason other than AE
    2
    2
    5
    2
    6
    Period 2
    Period 2 title
    Open Label Extension (OLE)
    Is this the baseline period?
    		 No
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 VX-509 150 mg qd - OLE
    Arm description
    		 VX-509 150 mg qd up to 104 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-509
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509 150 mg qd up to 104 weeks.

    Arm title
    		 VX-509 200 mg qd - OLE
    Arm description
    		 VX-509 200 mg qd up to 104 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-509
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    VX-509 200 mg qd up to 104 weeks.

    Number of subjects in period 2 [1]
    		VX-509 150 mg qd - OLE VX-509 200 mg qd - OLE
    Started
    47
    218
    Completed
    0
    0
    Not completed
    47
    218
         Required prohibited medication
    -
    1
         Death
    -
    1
         Did not meet eligibility criteria
    -
    8
         Adverse event
    2
    8
         Study terminated by sponsor
    42
    188
         Unspecified
    -
    5
         Lost to follow-up
    1
    1
         Refused further dosing for reason other than AE
    2
    6
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Only subjects who completed 24 weeks of treatment in the Treatment Period and who had at least an ACR20-CRP response were eligible for OLE.

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 VX-509-matched placebo up to 24 weeks.

    Reporting group title
    VX-509 100 mg qd
    Reporting group description
    		 VX-509 100 milligram (mg) once daily (qd) up to 24 weeks.

    Reporting group title
    VX- 509 150 mg qd
    Reporting group description
    		 VX-509 150 mg qd up to 24 weeks.

    Reporting group title
    VX-509 200 mg qd
    Reporting group description
    		 VX-509 200 mg qd up to 24 weeks.

    Reporting group title
    VX-509 100 mg bid
    Reporting group description
    		 VX-509 100 mg twice daily (bid) for up to 24 weeks.

    Reporting group values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid Total
    Number of subjects
    		 71 71 72 72 72 358
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 52.7 ( 13.16 ) 53.5 ( 11.33 ) 50.1 ( 11.81 ) 53.2 ( 13.21 ) 55.7 ( 12.23 ) -
    Gender categorical
    Units: Subjects
        Female
    		 62 51 58 56 62 289
        Male
    		 9 20 14 16 10 69

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 VX-509-matched placebo up to 24 weeks.

    Reporting group title
    VX-509 100 mg qd
    Reporting group description
    		 VX-509 100 milligram (mg) once daily (qd) up to 24 weeks.

    Reporting group title
    VX- 509 150 mg qd
    Reporting group description
    		 VX-509 150 mg qd up to 24 weeks.

    Reporting group title
    VX-509 200 mg qd
    Reporting group description
    		 VX-509 200 mg qd up to 24 weeks.

    Reporting group title
    VX-509 100 mg bid
    Reporting group description
    		 VX-509 100 mg twice daily (bid) for up to 24 weeks.
    Reporting group title
    VX-509 150 mg qd - OLE
    Reporting group description
    		 VX-509 150 mg qd up to 104 weeks.

    Reporting group title
    VX-509 200 mg qd - OLE
    Reporting group description
    		 VX-509 200 mg qd up to 104 weeks.

    Subject analysis set title
    VX-509 150 mg qd - Treatment Period, After Escape
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    Subjects with less than a 20% reduction from baseline in tender joints, swollen joints, and subject-assessed pain at Week 8 or later enrolled in Escape arm and received VX-509 150 mg qd.

    Subject analysis set title
    VX-509 200 mg qd - Treatment Period, After Escape
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    Subjects with less than a 20% reduction from baseline in tender joints, swollen joints, and subject-assessed pain at Week 8 or later were enrolled in Escape arm and received VX-509 200 mg qd.

    Primary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) C-Reactive Protein (ACR20-CRP) Response at Week 12

    		 Close Top of page
    End point title
    		 Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) C-Reactive Protein (ACR20-CRP) Response at Week 12
    End point description
    ACR20-CRP response: greater than equal to (>=) 20% improvement in tender joints count (TJC); >= 20% improvement in swollen joints count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: subject assessment of pain (assessed on 0-100 mm VAS, higher score = more pain); subject global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); physician global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and CRP levels. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Primary
    End point timeframe
    Week 12
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    71
    72
    72
    72
    Units: percentage of subjects
        number (not applicable)
    18.3
    46.5
    66.7
    56.9
    68.1
    Statistical analysis title
    		 Statistical Analysis 1
    Comparison groups
    VX-509 100 mg qd v Placebo
    Number of subjects included in analysis
    142
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0002
    Method
    		 Wald asymptotic test
    Parameter type
    		 Proportion difference
    Point estimate
    28.2
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 13.5
         upper limit
    		 42.8
    Statistical analysis title
    		 Statistical Analysis 2
    Comparison groups
    VX- 509 150 mg qd v Placebo
    Number of subjects included in analysis
    143
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Wald asymptotic test
    Parameter type
    		 Proportion difference
    Point estimate
    48.4
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 34.2
         upper limit
    		 62.5
    Statistical analysis title
    		 Statistical Analysis 3
    Comparison groups
    Placebo v VX-509 200 mg qd
    Number of subjects included in analysis
    143
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Wald asymptotic test
    Parameter type
    		 Proportion difference
    Point estimate
    38.6
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 24.1
         upper limit
    		 53.2
    Statistical analysis title
    		 Statistical Analysis 4
    Comparison groups
    VX-509 100 mg bid v Placebo
    Number of subjects included in analysis
    143
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Wald asymptotic test
    Parameter type
    		 Proportion difference
    Point estimate
    49.7
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 35.7
         upper limit
    		 63.8

    Primary: Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 12

    		 Close Top of page
    End point title
    		 Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 12
    End point description
    DAS28-4 (CRP) was calculated from SJC and TJC using the 28 joints count, CRP milligram per liter [mg/L] and subject general health visual analogue scale score. A score of less than (<2.6) implied remission, <=3.2 implied low disease activity. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Primary
    End point timeframe
    Baseline and Week 12
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    70
    70
    69
    71
    Units: units on scale
        least squares mean (standard error)
    -0.76 ( 0.157 )
    -2.05 ( 0.146 )
    -2.22 ( 0.14 )
    -2.48 ( 0.146 )
    -2.39 ( 0.142 )
    Statistical analysis title
    		 Statistical Analysis 1
    Comparison groups
    VX-509 100 mg qd v Placebo
    Number of subjects included in analysis
    141
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed effect model
    Parameter type
    		 Treatment difference
    Point estimate
    -1.28
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.68
         upper limit
    		 -0.88
    Statistical analysis title
    		 Statistical Analysis 2
    Comparison groups
    VX- 509 150 mg qd v Placebo
    Number of subjects included in analysis
    141
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed effect model
    Parameter type
    		 Treatment difference
    Point estimate
    -1.46
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -1.85
         upper limit
    		 -1.06
    Statistical analysis title
    		 Statistical Analysis 3
    Comparison groups
    VX-509 200 mg qd v Placebo
    Number of subjects included in analysis
    140
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed effect model
    Parameter type
    		 Treatment difference
    Point estimate
    -1.71
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -2.11
         upper limit
    		 -1.32
    Statistical analysis title
    		 Statistical Analysis 4
    Comparison groups
    VX-509 100 mg bid v Placebo
    Number of subjects included in analysis
    142
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed effect model
    Parameter type
    		 Treatment difference
    Point estimate
    -1.62
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -2.01
         upper limit
    		 -1.23

    Primary: Safety and Tolerability as Assessed by Adverse Events (AEs) Through Week 24

    		 Close Top of page
    End point title
    		 Safety and Tolerability as Assessed by Adverse Events (AEs) Through Week 24 [1]
    End point description
    AE: any untoward medical occurrence in a subject during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE included serious as well as non-serious AEs. Serious adverse event (SAE) (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Safety set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Primary
    End point timeframe
    Through Week 24
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical analysis was not planned for safety endpoint.
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: number of subjects
    number (not applicable)
        Subjects with AEs
    30
    37
    44
    49
    42
    11
    36
        Subjects with SAEs
    4
    3
    6
    5
    7
    1
    5
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Achieving ACR-CRP Responses

    		 Close Top of page
    End point title
    		 Percentage of Subjects Achieving ACR-CRP Responses
    End point description
    ACR20-CRP at Week 24 and ACR50/70-CRP at Week 12 and 24 are reported. ACR20-CRP is defined in first primary endpoint. ACR50/70-CRP response: >=50%/70% improvement in TJC; >=50%/70% improvement in SJC; and >=50%/70% improvement in at least 3 of 5 remaining ACR core measures: subject assessment of pain (assessed on 0-100 mm VAS, higher score = more pain); subject global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); physician global assessment of disease activity (assessed on 0-10 point scale, higher score = more disease activity); self-assessed disability (disability index of the HAQ); and CRP levels. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    71
    72
    72
    72
    Units: percentage of subjects
    number (not applicable)
        Week 24: ACR20 CRP
    16.9
    60.6
    61.1
    61.1
    62.5
        Week 12: ACR50 CRP
    7
    22.5
    38.9
    34.7
    38.9
        Week 12: ACR70 CRP
    2.8
    9.9
    11.1
    9.7
    22.2
        Week 24: ACR50 CRP
    7
    38
    38.9
    40.3
    47.2
        Week 24: ACR70 CRP
    2.8
    16.9
    18.1
    15.3
    25
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved a Moderate or Good Response with European League Against Rheumatism (EULAR) Response at Week 12 and 24

    		 Close Top of page
    End point title
    		 Percentage of Subjects who Achieved a Moderate or Good Response with European League Against Rheumatism (EULAR) Response at Week 12 and 24
    End point description
    DAS28-4 (CRP) EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28-4 (CRP) =< 3.2; moderate responders: change from baseline >1.2 with DAS28-4 (CRP) >3.2 or change from baseline >0.6 to =<1.2 with DAS28-4 (CRP) =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28-4 CPR >5.1. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    71
    72
    72
    72
    Units: percentage of subjects
    number (not applicable)
        Week 12
    25.4
    57.7
    69.4
    65.3
    68.1
        Week 24
    19.7
    56.3
    62.5
    61.1
    61.1
    No statistical analyses for this end point

    Secondary: Percentage of Subjects with DAS28-4 (CRP) Remission at Week 12 and 24

    		 Close Top of page
    End point title
    		 Percentage of Subjects with DAS28-4 (CRP) Remission at Week 12 and 24
    End point description
    DAS28-4 (CRP) is defined in second primary endpoint. DAS28-4 (CRP) score <2.6 was considered remission. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    71
    72
    72
    72
    Units: percentage of subjects
    number (not applicable)
        Week 12
    2.8
    16.9
    29.2
    22.2
    30.6
        Week 24
    5.6
    21.1
    29.2
    27.8
    31.9
    No statistical analyses for this end point

    Secondary: Change from Baseline in DAS28-4 (CRP) at Week 24

    		 Close Top of page
    End point title
    		 Change from Baseline in DAS28-4 (CRP) at Week 24
    End point description
    DAS28-4 (CRP) is defined in second primary endpoint. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    70
    70
    69
    71
    Units: units on scale
        least squares mean (standard error)
    -1.51 ( 0.215 )
    -2.35 ( 0.158 )
    -2.35 ( 0.148 )
    -2.68 ( 0.156 )
    -2.86 ( 0.154 )
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved Remission as Defined by the ACR/EULAR Criteria

    		 Close Top of page
    End point title
    		 Percentage of Subjects who Achieved Remission as Defined by the ACR/EULAR Criteria
    End point description
    Subject was considered to be in remission when either scores on the tender joint count, swollen joint count, CRP (in mg/dL), and subject global assessment (0 to 10 scale) were all <=1; or score on the Simplified Disease Activity Index (SDAI) was <=3.3. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    71
    72
    72
    72
    Units: percentage of subjects
    number (not applicable)
        Week 12
    0
    5.6
    5.6
    6.9
    6.9
        Week 24
    0
    9.9
    11.1
    6.9
    15.3
    No statistical analyses for this end point

    Secondary: Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12 and Week 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12 and Week 24
    End point description
    The HAQ-DI is a self-completed subject questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Domain score = total score of individual questions divided by total number of questions. HAQ-DI total score = total of domain scores divided by number of domains, range: 0 (best) to 3 (worst). Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid
    Number of subjects analysed
    71
    71
    72
    72
    72
    Units: units on scale
    least squares mean (standard error)
        Week 12
    -0.28 ( 0.071 )
    -0.49 ( 0.068 )
    -0.58 ( 0.065 )
    -0.63 ( 0.068 )
    -0.62 ( 0.066 )
        Week 24
    -0.6 ( 0.09 )
    -0.62 ( 0.07 )
    -0.65 ( 0.067 )
    -0.79 ( 0.069 )
    -0.75 ( 0.068 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Subject Global Assessment of Disease Activity at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Subject Global Assessment of Disease Activity at Week 12 and 24
    End point description
    Subject assessed overall arthritis activity on an 11-point scale ranging from 0 (none) to 10 (extreme). Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and Week 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: units on scale
    arithmetic mean (standard deviation)
        Week 12 (n= 39, 52, 59, 52, 58, 19, 45)
    -1.3 ( 2.31 )
    -2.6 ( 2.62 )
    -2.8 ( 2.13 )
    -2.8 ( 2.37 )
    -3.6 ( 2.66 )
    -2.2 ( 1.8 )
    -2.3 ( 1.88 )
        Week 24 (n= 17, 44, 53, 47, 50, 27, 55)
    -1.9 ( 3.2 )
    -3.9 ( 2.19 )
    -2.9 ( 2.46 )
    -3.7 ( 2.3 )
    -4.5 ( 2.34 )
    -3.4 ( 2.55 )
    -3.1 ( 2.8 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Subject Assessment of Pain Visual Analog Scale (VAS) Score at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Subject Assessment of Pain Visual Analog Scale (VAS) Score at Week 12 and 24
    End point description
    Subjects indicated the amount of pain they were experiencing using a 100 millimeter (mm) VAS. VAS range: 0 mm (no pain) to 100 mm (pain as bad as it could be). Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: millimeter (mm)
    arithmetic mean (standard deviation)
        Week 12 (n= 39, 52, 59, 52, 58, 19, 45)
    -10.1 ( 22.68 )
    -22.4 ( 26.57 )
    -24.4 ( 22.51 )
    -25.5 ( 25.17 )
    -31.6 ( 25.02 )
    -22.5 ( 18.67 )
    -22.1 ( 18.54 )
        Week 24 (n= 17, 44, 53, 47, 50, 27, 55)
    -19.3 ( 32.17 )
    -34.8 ( 22.3 )
    -25.8 ( 26.78 )
    -34.8 ( 25.38 )
    -41.4 ( 23.09 )
    -31.8 ( 24.99 )
    -30 ( 22.04 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Subject General Health VAS Score at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Subject General Health VAS Score at Week 12 and 24
    End point description
    Subjects rated their health using a 100 mm VAS. VAS range: 0 mm (very well) to 100 mm (extremely bad). Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: millimeter (mm)
    arithmetic mean (standard deviation)
        Week 12 (n= 39, 52, 59, 52, 58, 18, 45)
    -7.3 ( 24.3 )
    -18.6 ( 23.69 )
    -19.7 ( 24.69 )
    -21.2 ( 23.3 )
    -23.8 ( 26.17 )
    -21.6 ( 26.95 )
    -22.6 ( 24.48 )
        Week 24 (n= 17, 44, 53, 47, 49, 26, 55)
    -18.2 ( 33.1 )
    -24.2 ( 24.2 )
    -19 ( 23.89 )
    -28.9 ( 23.1 )
    -35.4 ( 25.41 )
    -29.3 ( 27.33 )
    -31.8 ( 24.15 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in the Physical Component and Mental Component of the Short Form-36 (SF-36) at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in the Physical Component and Mental Component of the Short Form-36 (SF-36) at Week 12 and 24
    End point description
    SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores (CS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Change from baseline in physical (PC) and mental component (MC) norm based scores (NBS) are reported. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: units on scale
    arithmetic mean (standard deviation)
        Week 12 – MC NBS (n= 39, 52, 59, 52, 58, 15, 42)
    2.056 ( 10.7207 )
    4.525 ( 11.5951 )
    5.022 ( 9.3893 )
    6.039 ( 10.8664 )
    5.886 ( 10.7011 )
    1.76 ( 10.5982 )
    3.558 ( 10.047 )
        Week 12 – PC NBS (n= 39, 51, 59, 52, 58, 15, 42)
    5.508 ( 7.7841 )
    6.116 ( 5.8375 )
    7.447 ( 7.2476 )
    8.642 ( 6.9517 )
    8.936 ( 8.4752 )
    5.482 ( 5.4057 )
    4.383 ( 5.4056 )
        Week 24 – MC NBS (n= 17, 44, 53, 47, 50, 27, 55)
    7.429 ( 12.3269 )
    4.641 ( 11.3092 )
    5.347 ( 10.068 )
    8.479 ( 9.9463 )
    7.705 ( 11.9373 )
    4.669 ( 9.4316 )
    4.157 ( 8.4898 )
        Week 24 – PC NBS (n= 17, 43, 53, 47, 50, 27, 55)
    10.411 ( 8.2095 )
    8.12 ( 6.9881 )
    9.066 ( 8.8524 )
    11.444 ( 7.9637 )
    11.168 ( 7.3012 )
    8.961 ( 8.5279 )
    6.977 ( 7.4528 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) Score at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) Score at Week 12 and 24
    End point description
    The RAQoL questionnaire is a 30-item self-administered measure that was specifically designed to assess the health-related quality of life of people with RA. Each item is in the form a simple statement to which subjects respond “Yes” or “No.” “Yes” scores 1 and “No” scores 0. The overall score is the sum of the individual item scores, ranging from 0 to 30, with a lower score indicating better quality of life. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: units on scale
    arithmetic mean (standard deviation)
        Week 12 (n= 39, 52, 59, 52, 58, 19, 45)
    -3.05 ( 7.247 )
    -5.37 ( 8.049 )
    -5.11 ( 5.272 )
    -6.67 ( 6.597 )
    -6.59 ( 7.923 )
    -2.37 ( 6.066 )
    -2.89 ( 7.101 )
        Week 24 (n= 17, 44, 53, 47, 50, 27, 55)
    -5.35 ( 9.219 )
    -7.34 ( 9.514 )
    -6.16 ( 6.404 )
    -8.76 ( 7.053 )
    -7.98 ( 7.249 )
    -4.78 ( 7.49 )
    -4.65 ( 6.692 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Subject-Assessed Duration of Morning Stiffness at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Subject-Assessed Duration of Morning Stiffness at Week 12 and 24
    End point description
    Morning stiffness was defined as stiffness in and around the joints, assessed by subject. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: minutes
    arithmetic mean (standard deviation)
        Week 12 (38, 51, 59, 52, 57, 19, 44)
    -37 ( 49.44 )
    -64.1 ( 63.19 )
    -60.4 ( 69.91 )
    -61.3 ( 49.71 )
    -73 ( 63.25 )
    -35.3 ( 88.65 )
    -39.9 ( 60.21 )
        Week 24 (16, 43, 52, 47, 50, 27, 54)
    -59.7 ( 68.03 )
    -71.5 ( 52.66 )
    -72.3 ( 71.22 )
    -67.1 ( 52.35 )
    -79.1 ( 74.01 )
    -72.4 ( 52.75 )
    -67.2 ( 71.91 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Functional Assessment of Chronic illness Therapy-Fatigue (FACIT-F) Scale Score at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Functional Assessment of Chronic illness Therapy-Fatigue (FACIT-F) Scale Score at Week 12 and 24
    End point description
    The FACIT-F is a 13-item self-administered tool that measures an individual’s level of fatigue during usual daily activities over the past week. The level of fatigue is measured on a five-point Likert-type scale from 4 = not at all fatigued to 0 = very much fatigued; some questions are reverse-scored. The FACIT-Fatigue score is the sum of the individual item scores multiplied by 13 and divided by the number of items answered; the range is 0 to 52, with higher scores indicating better quality of life. Full analysis set included all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: units on scale
    arithmetic mean (standard deviation)
        Week 12 (n= 39, 52, 59, 52, 58, 19, 45)
    5.13 ( 10.603 )
    5.76 ( 10.845 )
    6.36 ( 7.998 )
    8.49 ( 10.299 )
    10.39 ( 10.994 )
    3.11 ( 8.333 )
    3.38 ( 8.778 )
        Week 24 (n= 17, 44, 53, 47, 50, 27, 55)
    9.24 ( 12.77 )
    8.45 ( 11.487 )
    6.83 ( 9.468 )
    12.23 ( 11.309 )
    12.69 ( 10.017 )
    7.3 ( 11.207 )
    6.04 ( 8.604 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in Medical Outcomes Study-Sleep Module questionnaire (MOS-Sleep) Overall 9-Item Index Score at Week 12 amd 24

    		 Close Top of page
    End point title
    		 Change from Baseline in Medical Outcomes Study-Sleep Module questionnaire (MOS-Sleep) Overall 9-Item Index Score at Week 12 amd 24
    End point description
    The MOS Sleep Scale is a subject-rated questionnaire consisting of 12 items that assess the key constructs of sleep; assesses sleep for the 4 weeks prior to evaluation. The MOS Overall Sleep Problems Index is a 9-item sub-scale; norm based scores (NBS) range from 0 to 100, lower scores indicate fewer sleep problems. Full analysis set included all randomized subjects who received at least 1 dose of study drug
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: units on scale
    arithmetic mean (standard deviation)
        Week 12 (39, 51, 57, 51, 55, 19, 45)
    5.541 ( 10.2069 )
    6.162 ( 8.1018 )
    6.107 ( 7.0598 )
    5.752 ( 8.5562 )
    7.834 ( 7.6625 )
    2.143 ( 8.44 )
    5.862 ( 7.4288 )
        Week 24 (17, 44, 50, 44, 49, 27, 55)
    9.906 ( 13.1697 )
    6.953 ( 8.6609 )
    7.102 ( 6.4437 )
    8.325 ( 9.4486 )
    7.303 ( 7.8772 )
    4.471 ( 7.3857 )
    5.281 ( 7.0525 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in the EuroQol (EQ-5D) Total Score at Week 12 and 24

    		 Close Top of page
    End point title
    		 Change from Baseline in the EuroQol (EQ-5D) Total Score at Week 12 and 24
    End point description
    The EQ-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. Full analysis set included all randomized subjects who received at least 1 dose of study drug
    End point type
    Secondary
    End point timeframe
    Baseline, Week 12 and 24
    End point values
    		 Placebo VX-509 100 mg qd VX- 509 150 mg qd VX-509 200 mg qd VX-509 100 mg bid VX-509 150 mg qd - Treatment Period, After Escape VX-509 200 mg qd - Treatment Period, After Escape
    Number of subjects analysed
    71
    71
    72
    72
    72
    29
    64
    Units: units on scale
    arithmetic mean (standard deviation)
        Week 12 (n= 39, 52, 59, 52, 58, 19, 45)
    0.1413 ( 0.2555 )
    0.1313 ( 0.19425 )
    0.1146 ( 0.16821 )
    0.1767 ( 0.19794 )
    0.1621 ( 0.18571 )
    0.0634 ( 0.15886 )
    0.0785 ( 0.17708 )
        Week 24 (n= 17, 44, 52, 47, 50, 27, 55)
    0.1875 ( 0.27244 )
    0.1797 ( 0.24581 )
    0.136 ( 0.18494 )
    0.2294 ( 0.20718 )
    0.1974 ( 0.20298 )
    0.1305 ( 0.19656 )
    0.1093 ( 0.17024 )
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    First dose of study drug up to 28 days after last dose of study drug
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    15.0
    Reporting groups
    Reporting group title
    Placebo - Before Escape
    Reporting group description
    		 VX-509-matched placebo qd up to 24 weeks.

    Reporting group title
    VX-509 100 mg qd - Before Escape
    Reporting group description
    		 VX-509 100 mg qd up to 24 weeks.

    Reporting group title
    VX- 509 150 mg qd - Before Escape
    Reporting group description
    		 VX-509 150 mg qd up to 24 weeks.

    Reporting group title
    VX-509 200 mg qd - Before Escape
    Reporting group description
    		 VX-509 200 mg qd up to 24 weeks.

    Reporting group title
    VX-509 100 mg bid - Before Escape
    Reporting group description
    		 VX-509 100 mg bid up to 24 weeks.

    Reporting group title
    VX-509 150 mg qd - After Escape
    Reporting group description
    		 VX-509 150 mg qd up to 24 weeks.

    Reporting group title
    VX-509 200 mg qd - After Escape
    Reporting group description
    		 VX-509 200 mg qd up to 24 weeks.

    Reporting group title
    VX-509 150 mg qd - OLE
    Reporting group description
    		 VX-509 150 mg qd up to 104 weeks.

    Reporting group title
    VX-509 200 mg qd - OLE
    Reporting group description
    		 VX-509 200 mg qd up to 104 weeks.

    Serious adverse events
    		 Placebo - Before Escape VX-509 100 mg qd - Before Escape VX- 509 150 mg qd - Before Escape VX-509 200 mg qd - Before Escape VX-509 100 mg bid - Before Escape VX-509 150 mg qd - After Escape VX-509 200 mg qd - After Escape VX-509 150 mg qd - OLE VX-509 200 mg qd - OLE
    Total subjects affected by serious adverse events
         subjects affected / exposed
    4 / 71 (5.63%)
    3 / 71 (4.23%)
    6 / 72 (8.33%)
    5 / 72 (6.94%)
    7 / 72 (9.72%)
    1 / 29 (3.45%)
    5 / 64 (7.81%)
    6 / 47 (12.77%)
    22 / 218 (10.09%)
         number of deaths (all causes)
    0
    0
    0
    1
    1
    0
    0
    0
    1
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Lung neoplasm
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Deep vein thrombosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Umbilical hernia repair
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Breast mass
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adenomyosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    C-reactive protein increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Spinal compression fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tendon rupture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Angina unstable
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Right ventricular failure
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebral infarction
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vertigo CNS origin
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coma
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Orthostatic intolerance
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphadenitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphadenopathy
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Chorioretinitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Stomatitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mallory-Weiss syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Panniculitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Renal colic
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthritis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    2 / 2
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    3 / 218 (1.38%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchopneumonia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinusitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peritonitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary tuberculosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocarditis bacterial
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 Placebo - Before Escape VX-509 100 mg qd - Before Escape VX- 509 150 mg qd - Before Escape VX-509 200 mg qd - Before Escape VX-509 100 mg bid - Before Escape VX-509 150 mg qd - After Escape VX-509 200 mg qd - After Escape VX-509 150 mg qd - OLE VX-509 200 mg qd - OLE
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    29 / 71 (40.85%)
    36 / 71 (50.70%)
    43 / 72 (59.72%)
    47 / 72 (65.28%)
    41 / 72 (56.94%)
    11 / 29 (37.93%)
    36 / 64 (56.25%)
    28 / 47 (59.57%)
    118 / 218 (54.13%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Benign breast neoplasm
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Benign lymph node neoplasm
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Bowen's disease
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Lung neoplasm
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Squamous cell carcinoma
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Thyroid neoplasm
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    5 / 72 (6.94%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    2 / 47 (4.26%)
    8 / 218 (3.67%)
         occurrences all number
    0
    0
    2
    5
    1
    0
    0
    2
    9
    Hypotension
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    1
    0
    1
    0
    0
    0
    0
    Hot flush
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    0
    0
    Blood pressure fluctuation
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Haemorrhagic vasculitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Thrombosis
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Flushing
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Phlebitis superficial
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    Orthostatic hypotension
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    3 / 72 (4.17%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    0
    4
    1
    0
    0
    0
    1
    Malaise
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    7
    2
    0
    0
    0
    0
    0
    Pyrexia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    0
    Asthenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    5 / 218 (2.29%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    1
    5
    Chest discomfort
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Hunger
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Oedema peripheral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    1
    0
    Spinal pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    2
    Early satiety
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Influenza like illness
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Chest pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Inflammation
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Oedema
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Immune system disorders
    Contrast media allergy
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Hypersensitivity
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Seasonal allergy
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    2
    Reproductive system and breast disorders
    Breast mass
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Menstruation irregular
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Prostatitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    1
    Vaginal prolapse
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Vulvovaginal burning sensation
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Ovarian cyst
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Vaginal haemorrhage
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Adenomyosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Amenorrhoea
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Menopausal symptoms
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Vaginal inflammation
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    3 / 71 (4.23%)
    0 / 71 (0.00%)
    5 / 72 (6.94%)
    4 / 72 (5.56%)
    3 / 72 (4.17%)
    0 / 29 (0.00%)
    2 / 64 (3.13%)
    0 / 47 (0.00%)
    9 / 218 (4.13%)
         occurrences all number
    3
    0
    5
    4
    3
    0
    2
    0
    10
    Oropharyngeal pain
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    1
    1
    2
    2
    2
    0
    1
    1
    2
    Epistaxis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    3 / 72 (4.17%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    4
    0
    0
    1
    0
    Dyspnoea
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    1
    1
    Nasal congestion
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    2
    Pulmonary fibrosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Respiratory tract congestion
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Upper-airway cough syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Dysphonia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Sinus congestion
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Lung infiltration
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Pulmonary embolism
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    2
    1
    1
    0
    0
    0
    0
    2
    Anxiety
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    0
    0
    Depression
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    0
    2
    Abnormal dreams
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Nervousness
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    0
    Tension
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Depressed mood
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    Initial insomnia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Major depression
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Investigations
    Hepatic enzyme increased
         subjects affected / exposed
    2 / 71 (2.82%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    5 / 72 (6.94%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    2
    0
    4
    9
    2
    0
    0
    0
    2
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    5 / 72 (6.94%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    2 / 47 (4.26%)
    5 / 218 (2.29%)
         occurrences all number
    1
    0
    3
    5
    1
    0
    1
    2
    6
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    3 / 72 (4.17%)
    3 / 72 (4.17%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    3 / 218 (1.38%)
         occurrences all number
    0
    0
    2
    3
    3
    0
    0
    3
    3
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    4 / 72 (5.56%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    4 / 218 (1.83%)
         occurrences all number
    0
    0
    1
    2
    4
    0
    0
    1
    5
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    4 / 72 (5.56%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    4 / 218 (1.83%)
         occurrences all number
    0
    0
    0
    4
    1
    0
    1
    1
    4
    Blood triglycerides increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    3 / 72 (4.17%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    3
    1
    0
    1
    1
    0
    1
    Transaminases increased
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    1
    1
    1
    0
    0
    0
    0
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    3 / 218 (1.38%)
         occurrences all number
    0
    0
    0
    2
    1
    0
    0
    1
    3
    Cardiac murmur
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    0
    Blood pressure increased
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    2
    Electrocardiogram QT prolonged
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Human chorionic gonadotropin increased
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Liver function test abnormal
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    1
    Lymphocyte count increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Neutrophil count increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    0
    0
    Platelet count increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Red blood cell sedimentation rate increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    2
    1
    Weight decreased
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    White blood cell count decreased
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    White blood cell count increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Blood cholesterol increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    1
    2
    Low density lipoprotein increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    3 / 218 (1.38%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    1
    4
    Candida test positive
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Chest X-ray abnormal
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Blood prolactin increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Body temperature increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Lipids increased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    1 / 71 (1.41%)
    2 / 71 (2.82%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    4 / 218 (1.83%)
         occurrences all number
    1
    2
    4
    0
    0
    0
    0
    2
    4
    Contusion
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    3
    0
    1
    0
    1
    1
    3
    Ligament sprain
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    2 / 47 (4.26%)
    2 / 218 (0.92%)
         occurrences all number
    1
    0
    0
    1
    2
    0
    0
    2
    2
    Animal bite
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    1
    1
    0
    0
    0
    0
    0
    Limb injury
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    1
    0
    Bone fissure
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    0
    Excoriation
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Foot fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Laceration
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    0
    Post-traumatic pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skeletal injury
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    0
    0
    Tooth fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    1
    0
    Pubis fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Humerus fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Rib fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Ankle fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Arthropod bite
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Meniscus lesion
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Muscle strain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Road traffic accident
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Spinal compression fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Upper limb fracture
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Vaccination complication
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    2
    0
    1
    0
    1
    Atrioventricular block first degree
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    3 / 218 (1.38%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    0
    4
    Left ventricular hypertrophy
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    0
    Palpitations
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    1
    1
    Sinus bradycardia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    5 / 218 (2.29%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    5
    Ventricular extrasystoles
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    0
    0
    Angina pectoris
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Atrial fibrillation
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    2
    Bradycardia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Bundle branch block left
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    0
    Cardiac failure
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    1
    1
    Mitral valve incompetence
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Supraventricular extrasystoles
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Thrombophlebitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Conduction disorder
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Myocardial ischaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    1 / 71 (1.41%)
    6 / 71 (8.45%)
    7 / 72 (9.72%)
    6 / 72 (8.33%)
    6 / 72 (8.33%)
    0 / 29 (0.00%)
    2 / 64 (3.13%)
    0 / 47 (0.00%)
    6 / 218 (2.75%)
         occurrences all number
    3
    7
    17
    21
    6
    0
    2
    0
    6
    Dizziness
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    2
    2
    1
    0
    0
    0
    1
    Dysgeusia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    2
    2
    0
    0
    0
    0
    Migraine
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    3 / 218 (1.38%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    4
    Somnolence
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    2
    0
    0
    0
    0
    1
    Facial nerve disorder
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Neuropathy peripheral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Paraesthesia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    1
    Poor quality sleep
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Radicular pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Sleep paralysis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Tension headache
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Polyneuropathy
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Carpal tunnel syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Cluster headache
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hypotonia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Mental impairment
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Presyncope
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Sciatica
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Syncope
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Tremor
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    2 / 47 (4.26%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    2
    2
    Hypochromic anaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Leukopenia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Neutropenia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Thrombocytopenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    0
    Lymphopenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Anaemia megaloblastic
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Ear and labyrinth disorders
    Ear pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    1
    Tinnitus
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    0
    0
    Vertigo
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    2
    1
    0
    0
    0
    0
    Eye disorders
    Conjunctivitis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    1
    0
    1
    0
    0
    1
    0
    Dry eye
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    0
    1
    Conjunctivitis allergic
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    1
    Conjunctival ulcer
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    2
    Glaucoma
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Iritis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Blepharospasm
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Cataract
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Cataract subcapsular
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Keratitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    5 / 71 (7.04%)
    6 / 71 (8.45%)
    4 / 72 (5.56%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    2 / 47 (4.26%)
    2 / 218 (0.92%)
         occurrences all number
    7
    9
    4
    1
    2
    0
    0
    3
    3
    Nausea
         subjects affected / exposed
    4 / 71 (5.63%)
    2 / 71 (2.82%)
    3 / 72 (4.17%)
    2 / 72 (2.78%)
    3 / 72 (4.17%)
    1 / 29 (3.45%)
    2 / 64 (3.13%)
    1 / 47 (2.13%)
    3 / 218 (1.38%)
         occurrences all number
    4
    2
    6
    8
    3
    1
    2
    1
    5
    Abdominal pain upper
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    3 / 72 (4.17%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    1
    2
    3
    2
    1
    0
    1
    1
    2
    Dyspepsia
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    1
    1
    1
    2
    2
    0
    0
    0
    1
    Vomiting
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    3 / 72 (4.17%)
    3 / 72 (4.17%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    2 / 47 (4.26%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    3
    6
    0
    0
    1
    2
    1
    Gastritis
         subjects affected / exposed
    1 / 71 (1.41%)
    2 / 71 (2.82%)
    3 / 72 (4.17%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    1
    2
    3
    0
    0
    0
    0
    1
    2
    Abdominal pain
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    0
    3
    1
    0
    0
    1
    1
    Abdominal discomfort
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    2
    0
    1
    0
    0
    0
    0
    Constipation
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    1
    1
    0
    0
    0
    0
    2
    Abdominal pain lower
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    0
    0
    Dry mouth
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    0
    0
    0
    Glossodynia
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    0
    Toothache
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    1
    Abdominal distension
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Aphthous stomatitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Flatulence
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Food poisoning
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    1
    2
    Irritable bowel syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Mouth ulceration
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Peptic ulcer
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Stomatitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Tongue ulceration
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Colitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Cheilitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hypoaesthesia oral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Pancreatitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Periodontitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hepatobiliary disorders
    Hepatomegaly
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hyperbilirubinaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Liver disorder
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Cholelithiasis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    3 / 72 (4.17%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    3
    1
    0
    1
    0
    0
    2
    Rash
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    2 / 47 (4.26%)
    3 / 218 (1.38%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    2
    3
    Acne
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Alopecia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    1
    Dermatitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Ecchymosis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Nail disorder
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Onychoclasis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Pityriasis rosea
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Pruritus
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Rash papular
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    1
    Skin ulcer
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    1
    0
    Swelling face
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    1
    Dermatitis allergic
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    2
    Dermatitis contact
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    Dry skin
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Actinic keratosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Blister
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Hyperhidrosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    3
    Hyperkeratosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Psoriasis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Subcutaneous nodule
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Urticaria
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Renal and urinary disorders
    Leukocyturia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    0
    2
    2
    1
    0
    0
    5
    Dysuria
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    1
    0
    0
    1
    0
    0
    1
    Hypertonic bladder
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Renal colic
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Haematuria
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Nocturia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Renal cyst
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Urinary incontinence
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    6 / 218 (2.75%)
         occurrences all number
    0
    2
    2
    2
    0
    0
    0
    0
    6
    Myalgia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    1
    0
    1
    0
    0
    1
    0
    Rheumatoid arthritis
         subjects affected / exposed
    3 / 71 (4.23%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    6 / 218 (2.75%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    1
    6
    Rheumatoid nodule
         subjects affected / exposed
    2 / 71 (2.82%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    0
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    0
    0
    Muscle spasms
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    0
    2
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    0
    1
    2
    Neck pain
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    2
    Arthralgia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    2 / 47 (4.26%)
    3 / 218 (1.38%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    2
    3
    Bursitis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    2
    Exostosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Limb discomfort
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Lumbar spinal stenosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Nodal osteoarthritis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    0
    Osteoarthritis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    3 / 218 (1.38%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    3
    Osteopenia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Osteoporosis
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    1
    Pain in extremity
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    0
    Rotator cuff syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Tendonitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Sjogren's syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    Joint swelling
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    2 / 47 (4.26%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    1
    Foot deformity
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Spinal column stenosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    Arthritis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Flank pain
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Joint instability
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Metatarsalgia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Osteochondrosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Spinal osteoarthritis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Spondylolisthesis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Temporomandibular joint syndrome
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    2 / 71 (2.82%)
    3 / 71 (4.23%)
    1 / 72 (1.39%)
    4 / 72 (5.56%)
    3 / 72 (4.17%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    2 / 47 (4.26%)
    12 / 218 (5.50%)
         occurrences all number
    2
    7
    1
    4
    4
    1
    1
    3
    19
    Upper respiratory tract infection
         subjects affected / exposed
    2 / 71 (2.82%)
    3 / 71 (4.23%)
    1 / 72 (1.39%)
    3 / 72 (4.17%)
    3 / 72 (4.17%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    2 / 47 (4.26%)
    13 / 218 (5.96%)
         occurrences all number
    2
    3
    1
    3
    3
    1
    1
    2
    15
    Bronchitis
         subjects affected / exposed
    2 / 71 (2.82%)
    2 / 71 (2.82%)
    3 / 72 (4.17%)
    4 / 72 (5.56%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    3 / 64 (4.69%)
    0 / 47 (0.00%)
    12 / 218 (5.50%)
         occurrences all number
    3
    2
    3
    4
    0
    1
    3
    0
    14
    Gastroenteritis
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    4 / 72 (5.56%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    1
    3
    5
    1
    1
    0
    0
    0
    2
    Sinusitis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    3 / 72 (4.17%)
    2 / 72 (2.78%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    5 / 218 (2.29%)
         occurrences all number
    0
    1
    1
    3
    3
    0
    1
    0
    5
    Urinary tract infection
         subjects affected / exposed
    0 / 71 (0.00%)
    5 / 71 (7.04%)
    1 / 72 (1.39%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    3 / 64 (4.69%)
    1 / 47 (2.13%)
    5 / 218 (2.29%)
         occurrences all number
    0
    5
    1
    1
    0
    0
    3
    1
    6
    Pharyngitis
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    4 / 72 (5.56%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    2 / 47 (4.26%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    4
    1
    0
    1
    1
    2
    1
    Cystitis
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    2
    0
    2
    1
    0
    0
    1
    0
    Herpes zoster
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    8 / 218 (3.67%)
         occurrences all number
    0
    2
    1
    2
    0
    0
    1
    0
    8
    Rhinitis
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    2
    1
    0
    1
    0
    1
    1
    2
    Gastroenteritis viral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    2
    1
    0
    0
    1
    0
    1
    Influenza
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    1
    0
    2
    0
    0
    0
    0
    1
    2
    Respiratory tract infection
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    2
    0
    0
    1
    0
    0
    Herpes simplex
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    0
    0
    2
    Vaginal infection
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    0
    Viral infection
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    1 / 29 (3.45%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    3 / 218 (1.38%)
         occurrences all number
    1
    0
    0
    0
    1
    1
    1
    0
    3
    Vulvovaginal mycotic infection
         subjects affected / exposed
    1 / 71 (1.41%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    0
    5
    Breast infection
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Bronchopneumonia
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Dental fistula
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Furuncle
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Gastritis viral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Genital herpes
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Laryngitis
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Nail bed infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Oral candidiasis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    1
    2
    Oral fungal infection
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Oral herpes
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    0
    1
    Otitis media
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    1
    Post procedural infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Respiratory tract infection viral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    1
    Salmonellosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Soft tissue infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Subcutaneous abscess
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Tonsillitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    Tooth abscess
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    1
    Tooth infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    1 / 47 (2.13%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    1
    1
    Acute sinusitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Gastrointestinal viral infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Helicobacter infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Mycotoxicosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    1 / 29 (3.45%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Paronychia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    1
    Post procedural cellulitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Pneumonia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    2 / 218 (0.92%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    2
    Acute tonsillitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Borrelia infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Bronchitis viral
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Gastrointestinal infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Onychomycosis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Rash pustular
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    3
    Staphylococcal infection
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Tinea pedis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Tracheitis
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Urinary tract infection bacterial
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    1 / 47 (2.13%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Metabolism and nutrition disorders
    Hypercholesterolaemia
         subjects affected / exposed
    1 / 71 (1.41%)
    3 / 71 (4.23%)
    5 / 72 (6.94%)
    3 / 72 (4.17%)
    4 / 72 (5.56%)
    1 / 29 (3.45%)
    3 / 64 (4.69%)
    3 / 47 (6.38%)
    10 / 218 (4.59%)
         occurrences all number
    1
    3
    5
    3
    4
    1
    3
    3
    10
    Hyperlipidaemia
         subjects affected / exposed
    1 / 71 (1.41%)
    1 / 71 (1.41%)
    1 / 72 (1.39%)
    2 / 72 (2.78%)
    2 / 72 (2.78%)
    1 / 29 (3.45%)
    2 / 64 (3.13%)
    0 / 47 (0.00%)
    2 / 218 (0.92%)
         occurrences all number
    1
    1
    1
    2
    2
    1
    2
    0
    2
    Hypertriglyceridaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    2 / 71 (2.82%)
    3 / 72 (4.17%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    3 / 47 (6.38%)
    4 / 218 (1.83%)
         occurrences all number
    0
    2
    3
    0
    0
    0
    1
    3
    4
    Dyslipidaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    2 / 72 (2.78%)
    0 / 72 (0.00%)
    1 / 72 (1.39%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    5 / 218 (2.29%)
         occurrences all number
    0
    0
    2
    0
    1
    0
    1
    0
    5
    Dehydration
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    0 / 218 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Diabetes mellitus
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    1 / 72 (1.39%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    1 / 64 (1.56%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    1
    Increased appetite
         subjects affected / exposed
    0 / 71 (0.00%)
    1 / 71 (1.41%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Gout
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hypoglycaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Hypokalaemia
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Vitamin D deficiency
         subjects affected / exposed
    0 / 71 (0.00%)
    0 / 71 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 72 (0.00%)
    0 / 29 (0.00%)
    0 / 64 (0.00%)
    0 / 47 (0.00%)
    1 / 218 (0.46%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Jan 2012
    Updated baseline characteristics and secondary endpoints.
    03 Feb 2012
    Updated baseline characteristics and secondary endpoints.
    27 Sep 2012
    Clarified planned analysis.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The study was terminated early by the sponsor due to a decision to modify the drug development plan. The early termination was not due to a safety signal or lack of efficacy.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 18:42:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA